Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? by Jansen, S J T et al.
In women with early-stage breast cancer, adjuvant chemotherapy
may be given in addition to breast surgery and post-operative
radiotherapy. A recent overview of randomized trials (EBCTCG,
1998) showed that in women under the age of 50 with axillary-
node-positive breast cancer, the use of adjuvant chemotherapy
increases the mean estimated 5-year disease-free survival by
15.2% (from 41.9% to 57.1%). However, chemotherapy may be
associated with side effects such as nausea, hair loss and fatigue.
Therefore, the choice for adjuvant chemotherapy involves a trade-
off between the reduction in the risk of recurrence and the
potential deterioration in quality of life during and shortly after
treatment (Dodwell, 1998). 
The question is whether the application of adjuvant
chemotherapy in the treatment of early-stage breast cancer is
worthwhile (Dodwell, 1998). Nowadays, the use of adjuvant
chemotherapy for node-positive breast cancer in premenopausal
women is generally considered to be worthwhile because of the
clinical benefits (Fisher et al, 1997). The important issue is ‘how
low to go’ in applying adjuvant chemotherapy (Pritchard, 1997).
For example, women with node-negative disease between 50 and
69 years of age have a lower risk of recurrence compared to
younger women with node-positive disease and subsequently their
benefit from chemotherapy is smaller in absolute terms, namely 
an increase in the mean estimated 5-year disease-free survival of
6.3% (from 70.3% to 76.6%; EBCTCG, 1998). 
Studies have shown variations in the prescription of adjuvant
chemotherapy, e.g., between groups of American and European
oncologists and among different oncologists within those groups
(Rajagopal et al, 1994), among physicians in the UK (Sainsbury 
et al, 1995) and in the Netherlands (Stiggelbout et al, 2000),
among different groups of doctors (general practitioners, radio-
therapists, oncologists) and among different specialists within
those groups (Slevin et al, 1990). These studies show that the
trade-off between clinical benefits and the side effects of adjuvant
chemotherapy entails a difficult and complex decision process. In
this process, the patients’ own preferences and opinions are highly
relevant. The emphasis on patient autonomy and increasing shared
decision-making requires that the preferences and opinions of
patients regarding their treatment are assessed more explicitly. 
Patients’ preferences for treatments can be elicited by means of
a so-called treatment preference method or probability trade-off
method. This method requires the respondent to consider the side
effects of various treatment options together with the possible
outcomes of those treatments and the probabilities of obtaining
those outcomes (Llewellyn-Thomas et al, 1996). For a more elab-
orate discussion of the application of this approach in clinical
Patients’ preferences for adjuvant chemotherapy in
early-stage breast cancer: is treatment worthwhile? 
SJT Jansen1,2, J Kievit1, MA Nooij2, JCJM de Haes3, IME Overpelt1,2, H van Slooten4, E Maartense5 and 
AM Stiggelbout1
1Department of Medical Decision Making, K6-R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; 2Department of Clinical
Oncology, K1-P, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; 3Department of Medical Psychology, Academic Medical
Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands; 4Department of Internal Medicine, Diaconessen Hospital, PO Box 9650, 2300 RD Leiden, 
The Netherlands; 5Department of Internal Medicine, Reinier de Graaf Gasthuis, PO Box 5012, 2600 GA Delft, The Netherlands
Summary When making decisions about adjuvant chemotherapy for early-stage breast cancer, costs and benefits of treatment should be
carefully weighed. In this process, patients’ preferences are of major importance. The objectives of the present study were: (1) to determine
the minimum benefits that patients need to find chemotherapy acceptable, and (2) to explore potential preference determinants, namely:
positive experience of the treatment, reconciliation with the treatment decision, and demographic variables. Preferences were elicited from
patients scheduled for adjuvant chemotherapy (chemotherapy group: n = 38) before (T1), during (T2), and 1 month after chemotherapy (T3),
and were compared to responses from patients not scheduled for chemotherapy (no-chemotherapy group: n = 38). The patients were asked,
for a hypothetical situation, to indicate the minimum benefit (in terms of improved 5-year disease-free survival) to find adjuvant chemotherapy
acceptable. In the chemotherapy group, the median benefit was 1% at all 3 measurement points. In the no-chemotherapy group the attitude
towards chemotherapy became more negative over time, although not statistically significantly so (T1: 12%, T2: 15%, T3: 15%; P = 0.10). At all
measurement points, the patients in the chemotherapy group indicated that they would accept chemotherapy for significantly (P < 0.01) less
benefit than the patients in the no-chemotherapy group. Of the demographic variables, age was related to preferences, but only at T2 and only
in the no-chemotherapy group. The more positive attitude towards chemotherapy and the stability of preferences in the chemotherapy group
indicated that reconciliation with the treatment decision was a more important determinant of patients’ preferences than positive experience
of the treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: preferences; breast cancer; chemotherapy; cognitive dissonance reduction; shared decision-making 
1577
Received 5 September 2000 
Received 19 February 2001 
Accepted 19 March 2001
Correspondence to: SJT Jansen
British Journal of Cancer (2001) 84(12), 1577–1585
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1836, available online at http://www.idealibrary.com on  http://www.bjcancer.comdecision-making, see Llewellyn-Thomas et al (1996) and
Llewellyn-Thomas (1997). 
The literature has shown that there are several determinants that
may affect patients’ treatment preferences. Previous studies have
shown that patients are more willing than medical staff or the
general public to accept aggressive treatment in exchange for
small benefits (O’Connor, 1989; Slevin et al, 1990; Brundage et al,
1997). Thus, those who are actually ill are more likely to consider
treatment acceptable. Other studies have shown that respondents
tend to favour treatments that they had already experienced
(Yellen et al, 1994; McQuellon et al, 1995; Cullen et al, 1996;
Stiggelbout et al, 1996; Lindley et al, 1998; Nieuwkerk et al,
1998). 2 explanations have been proposed for this observation.
First, the patients’ satisfaction with the treatment, thus positive
experience of the treatment (Yellen et al, 1994; Cullen et al, 1996;
Stiggelbout et al, 1996; Lindley et al, 1998). Lindley et al (1998)
explain that the patients who had experienced chemotherapy in the
past might be less fearful of its potential negative effects and more
comfortable with their ability to cope with the physical, social and
emotional aspects of treatment. This explanation will be referred
to as ‘positive experience of the treatment’. 
The second explanation is based on a cognitive mechanism of
adaptation that people are known to use to justify the way in which
they were managed, also known as cognitive dissonance reduction
(Cullen et al, 1996; Lindley et al, 1998; Nieuwkerk et al, 1998).
Patients may have a desire to believe that the prior decision (for
treatment or no treatment) was the correct one (Lindley et al,
1998). This may make patients reluctant to reflect upon an alterna-
tive that was not proposed or that was turned down, but might have
been preferable. This explanation will be referred to as ‘reconcili-
ation with the treatment decision’. 
Other studies have shown that treatment preferences may be
affected by demographic variables: younger age (Yellen et al,
1994; McQuellon et al, 1995; Brundage et al, 1997), living with
others (e.g., a husband or a child; Yellen and Cella, 1995), being a
parent (Cullen et al, 1996), and having children living at home
(Yellen and Cella, 1995). All these variables are related to more
willingness to accept treatment. 
In our study, first, we wanted to determine the minimum benefit,
in terms of improved 5-year disease-free survival, that early-stage
breast cancer patients need before they are willing to accept adju-
vant chemotherapy, and see how this compares to the benefit
reported in the literature. For this purpose, we elicited preferences
for chemotherapy in early-stage breast cancer patients. 
Secondly, we wanted to study the impact of potential determi-
nants for the preferences: (1) positive experience of the treatment,
(2) reconciliation with the treatment decision, and (3) demo-
graphic variables. Specifically, to distinguish the first 2 determi-
nants, we elicited treatment preferences longitudinally from
patients scheduled for chemotherapy (chemotherapy group)
before, during, and after chemotherapy, and from patients not
scheduled for chemotherapy (no-chemotherapy group) at the same
points in time. 
Our hypothesis was that if having had positive experience with
chemotherapy determines preferences, then patients from both
groups should respond in the same way before the start of
chemotherapy as none have any experience with chemotherapy.
Subsequently, the preferences of treated patients should become
more positive during chemotherapy while the responses of the no-
chemotherapy patients should remain the same. If reconciliation
with the treatment decision determines the preferences, then we
would expect that the preferences of the patients in the chemo-
therapy group would be more positive towards chemotherapy
before the actual start of the treatment than the preferences of
patients not scheduled for chemotherapy. Finally, we examined
whether the preferences were affected by demographic variables
mentioned in the literature: age, living with others, being a parent
and having children living at home. 
PATIENTS AND METHODS 
Patients 
Between June 1996 and November 1999, consecutive early-stage
breast cancer patients were recruited from 5 hospitals in the west
of The Netherlands. Exclusion criteria were: the inability to write
or speak Dutch, previous personal experience with chemotherapy,
or a history of psychiatric illness. In addition, women under the
age of 56 years with 4 or more positive lymph nodes were
excluded from the study because they were eligible to participate
in a trial involving autologous bone marrow transplantation. 
All patients were treated according to treatment protocol and as
a result the 2 groups (chemotherapy and no-chemotherapy) will
differ in age and premenopausal status: The chemotherapy group
consisted of pre- or perimenopausal early-stage breast cancer
patients (node-positive and high-risk node-negative) who had
already consented to undergo chemotherapy. This was because we
did not want to interfere with personal treatment decisions. The
no-chemotherapy group included postmenopausal women with
positive or negative lymph nodes and pre- or perimenopausal
women with low-risk node-negative disease, who had not been
advised to have adjuvant chemotherapy. Some were scheduled for
hormonal therapy (Tamoxifen). 
Patients in the chemotherapy group were matched with patients
in the no-chemotherapy group on the basis of: personal experience
with radiotherapy, type of prior breast surgery (lumpectomy versus
mastectomy), time between surgery and first interview, inter-
viewer (1 of 3), and hospital in which treatment took place. There
were no obvious reasons to believe that these 5 characteristics
would influence the patients’ preferences towards adjuvant
chemotherapy. However, we attempted to make the 2 groups 
as similar as possible, except for the chemotherapy–no-
chemotherapy distinction, in order to make this latter comparison
as unconfounded as possible. We assumed that experiencing
hormonal therapy within the no-chemotherapy group would not
influence the patients’ preferences for adjuvant chemotherapy. 
The patients were interviewed 3 times: shortly before (T1),
during (T2), and one month after completion of chemotherapy (T3).
The second interview was held in the middle of treatment, in the
week before the third course for patients treated with 4 courses and
in the week before the fourth course for patients treated with 6
courses of chemotherapy. The patients in the no-chemotherapy
group were interviewed at comparable intervals. The same inter-
viewer performed all 3 interviews with each patient. 
Treatment preference instrument 
The treatment preference method used was an adapted version of
the decision board described by Levine et al (1992). Firstly,
patients were presented with hypothetical scenarios of the 2 treat-
ment choices: ‘no adjuvant chemotherapy, regular check ups’ or
‘adjuvant chemotherapy, regular check ups’ (see the Appendix).
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the expertise of 6 clinical oncologists, and the experiences of 5
breast cancer patients who were undergoing or who had recently
undergone adjuvant chemotherapy. The development of the
scenario is reported elsewhere (Jansen et al, 2000). The scenario
described the treatment programme as well as the potential side
effects. 
Second, the possible outcomes: ‘no recurrence within 5 years’
and ‘recurrence within 5 years’ were explained. Third, the proba-
bilities of each outcome were given for the 2 scenario descriptions.
Both the chances of recurrence and of no recurrence were
presented, i.e., a mixed frame was used to avoid the effect of
framing (O’Connor, 1989). A period of 5 years was chosen
because the main benefits of adjuvant chemotherapy for recur-
rence emerge during the first 5 years after treatment (EBCTCG,
1998). Recurrence was defined as the first reappearance of breast
cancer at any site (local, contralateral or distant), as is customary
in the clinical literature (for example EBCTCG, 1998). We used
the recurrence rates of patients with a good prognosis (Fisher et al,
1997), so as not to induce anxiety or distress. For the same reasons
the prognosis after recurrence was not stated explicitly. It was
emphasized to the patients that the probabilities of recurrence
mentioned in the treatment preference method probably did not
reflect their actual situation and that their individual benefit from
adjuvant chemotherapy was unknown to the researchers. 
The treatment preference instrument had been tested on 9
healthy volunteers (3 clinical oncologists and 6 co-workers) for
clarity of language, accuracy, and whether it provoked too much
distress. It was adapted where necessary. 
The patients were asked to think back to the time just after their
primary treatment and to imagine what they would have done if
they had been presented at that time with a choice between ‘ad-
juvant chemotherapy, regular check-ups’ and ‘no adjuvant
chemotherapy, regular check-ups’. Initially, the chance of ‘no
recurrence within 5 years’ without adjuvant chemotherapy was set
at 80% and the chance of ‘recurrence within 5 years’ at 20% (see
the Appendix). The benefit of chemotherapy was shown as an
increase in the chance of no recurrence from 80% to 90%, i.e., a
decrease in recurrence from 20 to 10%, thus an absolute benefit of
adjuvant chemotherapy of 10%. The patient was then asked to
choose between the 2 options. Next, the chance of no recurrence
without adjuvant chemotherapy was held at 80% while the chance
of no recurrence with adjuvant chemotherapy was set at 80% (a
benefit of 0%) or at 100% (a benefit of 20%), depending on the
patients’ initial choice. Then, again following the patients’ choice,
the chances were set at 85% or 95%, and, finally, fine-tuning was
carried out to 1%. The lowest chance of no recurrence at which a
patient switches from ‘no adjuvant chemotherapy, regular check
ups’ to ‘chemotherapy, regular check ups’ is the estimate of the
minimum benefit to find adjuvant chemotherapy acceptable, our
preference score. It was also possible to refuse chemotherapy if the
patient believed that for a benefit of 20% (the upper limit in this
study) adjuvant chemotherapy was not worthwhile. 
Statistical analysis 
Descriptive statistics were used to examine patient characteristics.
The baseline characteristics of the patients in the chemotherapy
group and in the no-chemotherapy group were compared using the
t-test for independent samples, the Mann–Whitney U-test for
nonparametric data, and the Chi-square test, where appropriate. 
If significant differences in baseline characteristics were found
between the groups, we looked in each group separately to see
whether these characteristics were related to preferences. This was
done by means of the Spearman-rank correlation coefficient or the
Mann–Whitney U-test, where appropriate. 
To explore the effects of the hypothesized determinants: posi-
tive experience of the treatment and reconciliation with the treat-
ment decision, the preferences of the patients in the chemotherapy
group were compared to the responses from the patients in the 
no-chemotherapy group at all 3 measurement points using
Mann–Whitney U-tests. Furthermore, the stability of the prefer-
ences was analysed for each group separately by means of the
Friedman test for non-parametric data. The stability of preferences
at the individual level was analysed by means of the Spearman-
rank correlation coefficient. 
Within each patient group, it was examined whether the prefer-
ences were determined by demographic variables: age (Spearman-
rank correlation coefficient), living with others, being a parent, and
having children living at home (Mann–Whitney U-test). 
RESULTS 
Patient characteristics 
Between June 1996 and November 1998, 71 early-stage breast
cancer patients who were eligible for participation in the
chemotherapy group were approached. 11 patients (15%) declined
participation, mostly because they were unwilling to talk about
their recent diagnosis of cancer. 13 patients (18%) could not be
interviewed before the start of the treatment for logistic reasons.*
47 patients participated in the first interview. 4 patients (9%)
dropped out between the first and second interview: 2 because
chemotherapy was prematurely terminated (leucopenia and
temporary deterioration in renal function) and 2 because of
psychological problems with the interview unrelated to the treat-
ment preference method.** 5 patients (11%) were excluded from
the analyses because their preferences were not available at T1, 3
for logistic reasons and 2 because they found the treatment prefer-
ence method too distressing at that time. This left 38 patients in the
chemotherapy group with a complete series of preferences. The
preferences of the patients who dropped out between the first and
second interview and of the patients whose preferences were not
available at T1 were similar to the preferences of the patients in the
ultimate chemotherapy group. 38 patients who were not treated
with adjuvant chemotherapy were selected in such a way that they
matched the patients in the chemotherapy group as closely as
possible. 
Table 1 shows clinical information of both patient groups and
Table 2 shows the demographics. 
The groups were compared for matching variables and other
clinical and demographic characteristics. Regarding the matching
variables, there were no significant differences between the 2
groups. Regarding the other characteristics, the patients in the
chemotherapy group more often had nodal involvement (89%
versus 37%, P < 0.01), had different disease profiles (P < 0.01),
were generally younger (42 years ± 5.5 versus 55 years ± 9.3, 
P < 0.01), and more frequently had children living at home (76%
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*These patients were interviewed after their first course of chemotherapy. They were
excluded in the analyses reported here for reasons of clarity. 
**This study is part of a larger study into the stability of breast cancer patients’
preferences. versus 39%, P < 0.01). These differences were inevitable since at
the time of the study the treatment protocol prescribed adjuvant
chemotherapy for women with nodal involvement under the age of
50, whereas for those above 50 hormonal therapy was the standard
treatment. The potential impact of the differences in clinical and
demographic characteristics between both patient groups for the
preferences will be discussed later. 
Minimum benefit to find chemotherapy acceptable 
The proportion of patients accepting adjuvant chemotherapy in
exchange for improved disease-free survival varied according to
the magnitude of the potential improvement in disease-free
survival (see Figures 1A and 1B). 
In the chemotherapy group, 39% of the patients responded that
they would be willing to accept adjuvant chemotherapy even if it
had no clinical benefit at all (0% benefit), averaged over the 3
measurement points. 1 patient responded that she was not willing
to accept chemotherapy at T1 and T2, whereas at T3 2 patients said
that they would refuse chemotherapy for any improvement in
disease-free survival. 
In the no-chemotherapy group on average (over the 3 measure-
ment points) 8% of the patients said that they would accept
chemotherapy for a benefit of 0% (see Figure 1B). About one third
of the patients in the no-chemotherapy group (T1: 34%, T2: 29%,
T3: 37%) responded that they would refuse chemotherapy no
matter what benefit. 
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Table 1 Clinical characteristics 
Chemotherapy group (n = 38) No-chemotherapy group (n = 38) Test for differences 
Clinical variables 
Time from surgery to first interview (in days)a NS 
Mean (SD) 72 (34.7) 82 (26.6) 
Range 17–153 20–134 
Lymph node metastasisc P<0.01 
Yes 34 (89%) 14 (37%) 
Prior therapyb NS 
Lumpectomy and radiotherapy 15 (39%) 17 (45%) 
Modified Radical Mastectomy and radiotherapy 12 (32%) 8 (21%) 
Modified Radical Mastectomy without radiotherapy 11 (29%) 13 (34%) 
Adjuvant therapy 
CMF 32 (84%) – 
AC 5 (13%) – 
FEC 1 (3%) – 
Tamoxifen not during chemotherapy 17 (45%) 
Disease profileb P < 0.01 
< 50 and lymph node positive 31 (82%) – 
³ 50 and lymph node positive 3 (8%)  14 (37%) 
< 50 and lymph node negative 4 (10%)  11 (29%) 
³ 50 and lymph node negative –  13 (34%) 
Hospitalb NS 
Leiden University Medical Center 11 (29%) 6 (16%) 
Diaconessen Hospital 10 (26%) 14 (37%) 
Rijnland Hospital 8 (21%) 15 (40%) 
Reinier de Graaf Gasthuis 7 (18%) 3 (8%) 
Groene Hart Hospital 2 (5%) – 
Interviewerb NS 
A 4 (11%) 4 (11%) 
B 21 (55%) 23 (61%) 
C 13 (34%) 11 (29%) 
at-test; bMann–Whitney U-test; cChi-square test. 
Table 2 Patient demographics 
Chemotherapy No-  Test  for
group chemotherapy differences 
(n = 38) group (n = 38)
Demographics
Agea P < 0.01 
Mean (SD) 42 (5.5) 55 (9.3) 
Range 29–50 38–77 
Marital statusb NS 
Married/living together 30 (79%) 28 (74%) 
Divorced 5 (13%) 1 (3%) 
Widowed – 3 (8%) 
Single 3 (8%) 6 (16%) 
Living with othersc NS 
Yes 34 (90%) 28 (74%) 
Being a parentc NS 
Yes 33 (87%) 31 (82%) 
Having children living at  P<0.01 
homec
Yes 29 (76%) 15 (39%) 
Educationb NS 
< 10 years 10 (26%) 11 (29%) 
10–15 years 13 (34%) 16 (42%) 
> 15 years 15 (39%) 11 (29%) 
Occupational statusb NS 
Full-time employment 14 (37%) 5 (13%) 
Part-time employment 20 (53%) 17 (45%) 
Housewife 4 (11%) 16 (42%) 
at-test; bMann–Whitney U-test; cChi-square test. Determinants of treatment preference scores 
The median preference scores as well as the interquartile ranges
in both patients groups are presented in Table 3. At T1, before
the chemotherapy group actually obtained experience with chemo-
therapy, significant differences were found between the prefer-
ences of the patients in the chemotherapy group and those of the
patients in the no-chemotherapy group. The patients in the latter
group needed more benefit from adjuvant chemotherapy before
they would be willing to accept this treatment (median scores: 1%
versus 12%, P < 0.01). These differences were also found at T2 and
T3 (median scores: 1% versus 15%, P < 0.01). 
In both groups, the preferences remained stable over time.
Although the patients in the no-chemotherapy group were somewhat
more negative towards chemotherapy at T2and T3than at T1, this did
not reach statistical significance. In the chemotherapy group, the
Spearman-rank correlation coefficient between the preferences
obtained at T1 and T2 was 0.66 (P < 0.01) and 0.63 
(P < 0.01) between the preferences obtained at T2 and T3. In the no-
chemotherapy group, the Spearman-rank correlation coefficients
were 0.57 (P < 0.01) and 0.64 (P < 0.01), respectively. These results
show that the individual preferences are reasonably reliable. 
We hypothesized that if having had positive experience with
chemotherapy determines preferences, then the preferences of
treated patients should become more positive during chemotherapy
while the preferences of the patients in the no-chemotherapy group
should remain the same over time. If reconciliation with the treat-
ment decision determines the preferences, then we would expect
that the preferences of the patients in the chemotherapy group
would be more positive towards chemotherapy before the actual
start of the treatment than the preferences of the patients in the no-
chemotherapy group. The results suggest that reconciliation with
the treatment decision is a more important determinant of prefer-
ences than positive experience of the treatment. 
To support this outcome it has to be ruled out that the differ-
ences in preferences between both patient groups are related to the
differences in clinical and demographic characteristics that were
found between the 2 groups. To examine this, the relationships
between the baseline characteristics in question (nodal status,
disease profile, age, and having children living at home) and the
preferences were analysed, in each group separately. No signifi-
cant differences in preferences were found between the patients
with positive and negative lymph nodes, or between the patients
with various disease profiles (based on age and lymph node
status). In the no-chemotherapy group, a significant effect (P <
0.05) was found for age at T2 (Spearman-rank correlation coeffi-
cient: 0.35, n = 38), indicating that younger patients would be
willing to accept chemotherapy for less benefit than older patients.
In the chemotherapy group, no such effect was found. The prefer-
ences of patients with children living at home were not signifi-
cantly different from those without. 
Finally, we examined whether the preferences were affected by
demographic variables that are known from the literature to be
related to the willingness to accept treatment. The variables age and
having children living at home have been discussed above, which
leaves the variables living with others and being a parent. A
Mann–Whitney U-test showed no differences in preferences
between patients who lived alone and those who were living with
others. Moreover, no significant differences in preferences were
found between patients who had children and those without children. 
A Mann–Whitney U-test showed that in the no-chemotherapy
group the preferences did not differ significantly between patients
treated with Tamoxifen and those not treated with Tamoxifen. This
supports our assumption that hormonal therapy did not influence
decisions for adjuvant chemotherapy. 
DISCUSSION 
The purpose of this study was 2-fold. First, to establish the
minimum benefits that early-stage breast cancer patients need
before they are willing to accept adjuvant chemotherapy. Second,
to explore previously described determinants of preferences. 
Minimum benefit to find chemotherapy acceptable 
In patients undergoing chemotherapy, the median minimum benefit
to find chemotherapy acceptable was 1% at all 3 measurement
Patients’ preferences for adjuvant chemotherapy 1581
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Figure 1 A  Cumulative proportion of patients in chemotherapy group 
(n = 38) willing to accept adjuvant chemotherapy according to minimum
percentage of benefit, measured before (T1), during (T2), and after (T3)
chemotherapy. B Cumulative proportion of patients in no-chemotherapy
group (n = 38) willing to accept adjuvant chemotherapy according to
minimum percentage of benefit, measured at baseline (T1), three months
thereafter (T2), and 6 months thereafter (T3) points. On average, 94% of patients indicated a willingness to accept
adjuvant chemotherapy for a 15% (or less) improvement in 5-year
disease-free survival, which is the mean benefit in 5-year disease-free
survival for early-stage breast cancer patients under the age of 50
with positive lymph nodes according to a recent overview of
randomized trials (EBCTCG, 1998). There seems to be no doubt that
the actual prescription of adjuvant chemotherapy in this patient group
was in accordance with the patients’ preferences for a hypothetical
situation obtained by means of a treatment preference instrument. 
In patients not undergoing chemotherapy, the median minimum
benefit to find chemotherapy acceptable was 12%, 15% and 15%
at T1, T2 and T3, respectively. Because these patients were gener-
ally older and were more likely to have negative lymph nodes,
their absolute benefit from adjuvant chemotherapy would be less
than that of the patients in the chemotherapy group. The best mean
estimates of benefits of chemotherapy in 5-year disease-free
survival are 6.7%, 9.4% and 6.3% for patients between 50 and 69
years with positive lymph nodes, for patients under the age of 50
with negative lymph nodes, and for patients between 50 and 69
years with negative lymph nodes, respectively (EBCTCG, 1998).
Because these subgroups are fairly evenly represented in the no-
chemotherapy group (see Table 1), and because no significant
differences were found between the preferences of the patients in
the various subgroups that were based on disease profiles, the best
mean estimate of benefit in the no-chemotherapy group is approx-
imately 7% (the mean benefit of the 3 subgroups). 
In this study, on average 26% of the patients in the no-
chemotherapy group stated that they would accept adjuvant
chemotherapy for a benefit of 7% or less (T1: 39%; T2: 26%; T3:
13%). These results seem to indicate that not prescribing adjuvant
chemotherapy in this patient group is according to the preferences of
75% of the patients. However, we cannot be sure that the patients in
the no-chemotherapy group would have accepted chemotherapy in
a real life situation for less benefit. Would they have accepted
chemotherapy if the doctor had proposed it as a real choice?
Siminoff and Fetting (1991) found that the strongest predictor
for the treatment decisions of patients with a life-threatening illness
was the physician’s primary treatment recommendation. We do not
know whether the patients in our study discussed the option of adju-
vant chemotherapy with their specialists. Most likely they were not
offered chemotherapy and did not ask for it. 
Determinants of treatment preference scores 
Studies have shown that subjects are more willing to accept treat-
ments of which they have personal experience (Yellen et al, 1994;
McQuellon et al, 1995; Cullen et al, 1996; Stiggelbout et al, 1996;
Lindley et al, 1998; Nieuwkerk et al, 1998). In this study, we
examined which was the more important determinant of prefer-
ences: (1) positive experience of the treatment or (2) reconciliation
with the treatment decision. The first explanation is based on the
patients’ satisfaction with the treatment that they have experi-
enced. The second implies that patients may have a desire to
believe that the prior decision was the correct one (Lindley et al,
1998) and that they will try to justify this decision. This is based
on the psychological mechanism referred to as ‘cognitive disso-
nance reduction’ (Berkowitz, 1986). 
The apparent stability in preferences that was found over time
in the chemotherapy group seems to exclude the positive experi-
ence of treatment explanation. Moreover, the large differences in
preferences between the 2 groups, even before the start of the
treatment, seem to support the idea of reconciliation with the
treatment decision as a determinant of preferences. In this study,
the prior decision refers to the decision to accept chemotherapy
by the patients in the chemotherapy group and the decision
to accept either no adjuvant treatment or hormonal treatment by
the patients in the no-chemotherapy group. After the treatment
choice has been made, patients may be unwilling to think about
the alternative that was not proposed, but might have been
preferable (Cullen et al, 1996), or upon the alternative that was
turned down. This may result in more positive preferences for
chemotherapy in the chemotherapy group than in the no-
chemotherapy group. 
With regard to other potential determinants of preferences, our
results did not show influences on the patients’ preferences of:
nodal status, disease profile, treatment with Tamoxifen, living with
others, being a parent, and finally, having children living at home.
The observation that the patients in the chemotherapy group were
significantly younger than those in the no-chemotherapy group
might have had an impact on their preferences. However, a statis-
tically significant relationship between age and preferences was
found only at T2 in the no-chemotherapy group. This relationship
was moderate (r = 0.35, P < 0.05). Previous studies that observed
relationships between age and treatment preferences have also
found only moderate relationships. Brundage et al (1997)
observed a non-significant tendency that a higher proportion of
patients younger than 60 years would accept combined chemo-
radiotherapy as compared with older patients. In the study by
McQuellon et al (1995), younger subjects were more likely to
accept treatment, but this effect was modest and observed only for
a prolongation of survival of 6 months and not in the case of 5
years, 18 months, 1 year, 1 month and 1 week. Yellen et al (1994)
concluded that older patients differ in terms of willingness to trade
survival for current quality of life only when treatment is
presumed and not in terms of acceptance of chemotherapy. The
results of these studies, as well as the absence of an association at
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Table 3 Median scores and interquartile ranges (IQR) of the minimum benefit to find chemotherapy acceptable in early-stage breast cancer patients
undergoing adjuvant chemotherapy (n = 38) and not undergoing adjuvant chemotherapy (n = 38). Preferences were elicited before (T1), during (T2), and after
(T3) chemotherapy or at similar points in time in the no-chemotherapy group 
T1 T2 T3
P value for
differences 
Median(%) IQR Median(%) IQR Median(%) IQR 
over time
Chemotherapy group 1 0–5 1  0–5 1 0–10  P = 0.67 
No-chemotherapy group 12 3–20 15  5–20 15 13–20 P = 0.10 
P value for differences between groups P < 0.01 P < 0.01 P < 0.01T1 and T3, may support our assumption that the differences in pref-
erences between the 2 groups may only to a small extent be
explained by differences in age. 
There may, however, be other aspects that determine prefer-
ences than we have explored in this study. According to Yellen and
Cella (1995), the most important predictor of whether a patient
will accept a potentially aggressive treatment may be the way in
which the treatment is described by the oncologist, and how
strongly it is recommended. This may have played a role in our
study results because the preferences were elicited after the actual
decision for treatment was made. Most probably, the specialists’
recommendations for adjuvant chemotherapy were stronger in the
chemotherapy group than in the no-chemotherapy group. 
Accepting adjuvant chemotherapy for no clinical
benefit 
The most remarkable observation we made is that almost 40% of
the patients undergoing chemotherapy and 8% of the patients not
eligible for chemotherapy responded that they would accept
chemotherapy if it had no clinical benefit at all. Similar findings
were observed in other studies. Yellen and Cella (1995) observed
that 45% of cancer patients stated that they would accept mildly
toxic adjuvant therapy for 1% increase in likelihood of cure. In the
study by Ravdin et al (1998), the median acceptable reduction of
risk of recurrence at 5 years of follow-up was 0.5% to 1% in early-
stage breast cancer patients who previously had received adjuvant
chemotherapy. Finally, Palda et al (1997) observed that 46% of
breast cancer patients would not give up post-operative radio-
therapy, even in the face of no stated benefit. 
In the present paper, the benefit of adjuvant chemotherapy is
described in terms of an improvement in 5-year disease-free
survival, thus a clinically defined benefit. However, adjuvant
chemotherapy may have other benefits for patients. For example,
Levine et al (1988) observed, through unstructured interviews, that
chemotherapy can provide women with a sense of control over
their lives and with a feeling that they are doing something active
to deal with their disease. Chemotherapy may help to handle the
feeling of helplessness that accompanies the diagnosis of breast
cancer. Palda et al (1997) observed that 57% of patients who were
willing to accept post-operative radiotherapy for zero benefit, had a
positive, persistent belief in the treatment benefits: they ‘felt better’
or were ‘convinced/know/believe/certain that it will help’. Other
patients used more negative terms, such as ‘worry’, ‘fear’, ‘regret’
and ‘doubt’. These kinds of motivations will also have contributed
to the acceptance of chemotherapy for small or no clinical benefit in
this study. Our patients remarked spontaneously that this was the
case; e.g., ‘At least, I have done everything I could’. In addition,
anticipated regret (Bell, 1982) seems to have played a role; ‘In the
future, I do not want to regret having refused chemotherapy’.
If we adhere to patient autonomy and shared decision-making,
are we willing to give burdening treatments to patients for cogni-
tive and affective reasons? Since more and more attention is
focused on shared decision-making and patient autonomy, further
research into the (ir)rationality of patients’ preferences will be
necessary. Patients can make choices that are based on criteria or
points of views that may seem irrational to the outsider. If a
patient’s goal is to live at all costs and if she believes that
chemotherapy may help her, no matter what the doctors say, the
choice to accept chemotherapy may be highly rational. However, if
we define a rational decision as one that complies with the principles
of expected utility, it is clear that accepting a potential aggressive
treatment without expected benefit is not a rational choice. To
what extent should a health care system, or society, tolerate such
‘irrational’ choices by well-informed and autonomous patients?
Subsequently, if there are limits to the ‘irrationality’ that society
tolerates, and is willing to pay for, who is going to set these limits,
and how? These questions need to be solved before the ‘irrational’
choices we found can be dealt with. 
Limitations and future directions 
The generalization of our study results is limited by the differences
between both patients groups with respect to clinical and
demograpical characteristics. Another limitation is that the minimum
benefit to find adjuvant chemotherapy acceptable is assessed in a
hypothetical situation and may not reflect the minimum benefits the
patients would need in a real-life situation. As a consequence of the
process of reconciliation with the treatment decision the preferences
presented here may be too positive in the patients undergoing
chemotherapy and too negative in the patients not scheduled for
chemotherapy. Studies into treatment preferences have been carried
out in patients who have already undergone the particular treatment
(Nieuwkerk et al, 1998; Ravdin et al, 1998; Silvestri et al, 1998), in
mixed patient groups with some patients having experience and
others not (O’Connor, 1989; Kiebert et al, 1993; Yellen et al, 1994;
McQuellon et al, 1995; Yellen and Cella, 1995; Cullen et al, 1996;
Elit et al, 1996; Brundage et al, 1997; Lindley et al, 1998), in patients
who were about to undergo the specific treatment (Slevin et al, 1990;
Palda et al, 1997), or in respondents who did not receive the treat-
ment under concern (McNeil et al, 1982; Llewellyn-Thomas et al,
1996). As a result, all studies mentioned above have been carried out
in a hypothetical situation and may have been influenced by the
effect of ‘reconciliation with the treatment decision’. The finding in
our study that ‘reconciliation with the treatment decision’ may have
such a large impact on the preferences for treatment has important
consequences for the field of oncology in that the results of previ-
ously published preference studies must be interpreted with caution.
As far as we know only 2 pilot studies have used a treatment prefer-
ence instrument in an actual decision-making situation to assist
women with breast cancer to decide whether or not to receive 
post-operative radiotherapy (Whelan et al, 1995) or adjuvant
chemotherapy (Levine et al, 1992). We recommend that future
studies into patients’ preferences be performed in patients before the
actual treatment decision has been made. By repeating the measure-
ments after the treatment decision the potential impact of ‘reconcili-
ation with the treatment decision’ can be determined in other patient
groups and with other treatments. 
In conclusion, in decision-making on adjuvant chemotherapy
for breast cancer both patients and doctors should be aware that
patients’ preferences may not only be based on clinical factors but
also be influenced by cognitive and affective factors. Moreover,
these determinants may have such a strong impact that even treat-
ment without obvious clinical benefit, and with possible side
effects, may be considered worthwhile by patients. 
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Chemotherapy, regular check-ups  90%  ® No recurrence within 5 years
During 6 months 1 or 2 hospital  All tests and examinations show that
visits per 3 weeks for chemotherapy  there is no recurrence of the cancer.
treatment intravenously.  One may sometimes worry that the
During and after chemotherapy regular  tumour may return. 
check-ups.
The following side effects and 
psychological and social consequences  10%  ® Recurrence within 5 years
may occur: The tumour may recur in the breast or 
Physical: Nausea, fatigue, hair loss, at a different site in the body. 
difficulty in carrying out strenuous  Various treatments may follow like 
activities, frequent need to rest  radiotherapy, chemotherapy or 
Psychological: Dissatisfaction with  hormonal therapy. The prognosis is 
one’s body  uncertain. 
Social: Limitations to work or other 
daily activities, restrictions on social 
No chemotherapy, regular check-ups 80%  No recurrence within 5 years
Each check-up includes a physical  All tests and examinations show that 
examination. A mammogram is made  there is no recurrence of the cancer.
once a year.  One may sometimes worry that the 
tumour may return. 
The side effects and especially the 
psychological and social consequences as 
mentioned with chemotherapy may also 
occur in this option as a result of previous 
surgery, radiotherapy or the diagnosis of  20%  Recurrence within 5 years 
cancer. The tumour may recur in the breast 
or at a different site in the body. 
Various treatments may follow like 
radiotherapy, chemotherapy or 
hormonal therapy. The prognosis is 
uncertain.
APPENDIX 
Description of treatment preference method. Chances of recurrence and of no-recurrence for ‘no chemotherapy, regular check-ups’ are
held constant while chances of recurrence and of no-recurrence for ‘chemotherapy, regular check-ups’ are varied according to respondent’s
preferences. The point where the respondent switches from ‘no chemotherapy’ to ‘chemotherapy’ indicates the minimum benefit to find
chemotherapy acceptable.  
Treatment option Chance of outcome Outcome 